Exagen/$XGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Exagen
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Ticker
$XGN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
212
ISIN
US30068X1037
Website
Exagen Metrics
BasicAdvanced
$153M
-
-$0.84
1.51
-
Price and volume
Market cap
$153M
Beta
1.51
52-week high
$7.95
52-week low
$2.67
Average daily volume
242K
Financial strength
Current ratio
2.323
Quick ratio
1.852
Long term debt to equity
310.729
Total debt to equity
367.921
Interest coverage (TTM)
-6.28%
Profitability
EBITDA (TTM)
-12.292
Gross margin (TTM)
59.30%
Net profit margin (TTM)
-27.34%
Operating margin (TTM)
-24.68%
Effective tax rate (TTM)
-0.08%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-19.21%
Return on equity (TTM)
-117.50%
Valuation
Price to revenue (TTM)
2.259
Price to book
19.57
Price to tangible book (TTM)
19.57
Price to free cash flow (TTM)
-8.292
Free cash flow yield (TTM)
-12.06%
Free cash flow per share (TTM)
-84.18%
Growth
Revenue change (TTM)
1.78%
Earnings per share change (TTM)
-22.40%
3-year revenue growth (CAGR)
5.65%
10-year revenue growth (CAGR)
14.51%
3-year earnings per share growth (CAGR)
-22.58%
10-year earnings per share growth (CAGR)
-44.15%
Exagen News
AllArticlesVideos
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
GlobeNewsWire·1 week ago
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares
GlobeNewsWire·2 months ago
Exagen Inc. Prices Public Offering of Common Stock
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Exagen stock?
Exagen (XGN) has a market cap of $153M as of July 01, 2025.
What is the P/E ratio for Exagen stock?
The price to earnings (P/E) ratio for Exagen (XGN) stock is 0 as of July 01, 2025.
Does Exagen stock pay dividends?
No, Exagen (XGN) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next Exagen dividend payment date?
Exagen (XGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Exagen?
Exagen (XGN) has a beta rating of 1.51. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.